Head-To-Head Survey: CRISPR Therapeutics (CRSP) and Its Peers

CRISPR Therapeutics (NASDAQ:CRSP) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare CRISPR Therapeutics to related companies based on the strength of its institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and target prices for CRISPR Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1	8	8	2	2.58
CRISPR Therapeutics Competitors	9839	15124	45438	1588	2.54

CRISPR Therapeutics currently has a consensus target price of $69.69, suggesting a potential upside of 39.18%. As a group, “Biotechnology” companies have a potential upside of 103.34%. Given CRISPR Therapeutics’ rivals higher possible upside, analysts plainly believe CRISPR Therapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares CRISPR Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-1,812.07%	-25.59%	-17.89%
CRISPR Therapeutics Competitors	-12,346.73%	-197.60%	-30.56%

Institutional & Insider Ownership

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares CRISPR Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CRISPR Therapeutics	$3.51 million	-$581.60 million	-10.56
CRISPR Therapeutics Competitors	$715.93 million	$12.70 million	-15.10

CRISPR Therapeutics’ rivals have higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

CRISPR Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics’ rivals have a beta of 1.10, suggesting that their average share price is 10% more volatile than the S&P 500.

Summary

CRISPR Therapeutics beats its rivals on 8 of the 13 factors compared.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.